Research - Page 16 of 719 Posts on Medivizor

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Posted by Medivizor on Dec 31, 2022 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of encorafenib (Braftovi) alone or in combination with binimetinib (Mektovi) or vemurafenib (Zelboraf) alone in patients with BRAF-mutated advanced melanoma. The data showed that the encorafenib plus binimetinib combination lead to long-term effectiveness and no new safety...

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by Medivizor on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by Medivizor on Dec 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Posted by Medivizor on Dec 31, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding oxaliplatin (Eloxatin; 3 months vs 6 months) to 6 months of fluoropyrimidine therapy such as 5-Fluorouracil (Adrucil) or capecitabine (Xeloda) as adjuvant (treatment after surgery) treatment in patients with stage II or III colon cancer. The data showed that adding 3 months of...

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by Medivizor on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Evaluating the long-term effectiveness and safety of bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia.

Posted by Medivizor on Dec 30, 2022 in Leukemia | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of bosutinib (Bosulif) versus imatinib (Gleevec) in patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML). The data showed that bosutinib had better effectiveness than imatinib in these patients. Some background CML is a type of cancer that starts...

Comparing the effectiveness and safety between biodegradable and durable polymer drug-eluting stents in patients with acute coronary syndrome.

Posted by Medivizor on Dec 30, 2022 in Coronary artery disease | 0 comments

In a nutshell This study compared the effectiveness and safety between biodegradable polymer (BP) drug-eluting stents (DES) and durable polymer (DP) DESs in patients with acute coronary syndrome (ACS). The data showed that both stent types demonstrated excellent effectiveness and safety after 1 year. The authors suggested that BP-DES may be more...

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Posted by Medivizor on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Posted by Medivizor on Dec 30, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the effects of carbohydrate-restricted diets and intermittent fasting (IF) in patients with obesity, type 2 diabetes (T2D), and hypertension (high blood pressure). The authors recommended that in adults with T2D, overweight or obesity, a moderately-low carbohydrate diet can be considered as a dietary...

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Posted by Medivizor on Dec 30, 2022 in Hypertension | 0 comments

In a nutshell This study evaluated the effects of carbohydrate-restricted diets and intermittent fasting (IF) in patients with obesity, type 2 diabetes (T2D), and hypertension (high blood pressure). The authors recommended that in adults with T2D, overweight or obesity, a moderately-low carbohydrate diet can be considered as a dietary regimen for blood...

Does hyaluronic acid gel reduce intrauterine adhesions after surgery in women with miscarriage?

Posted by Medivizor on Dec 30, 2022 in Infertility | 0 comments

In a nutshell This study evaluated whether hyaluronic acid gel (HAG) reduces intrauterine adhesions (IUAs) after curettage in women with a miscarriage. The data showed that HAG reduces the rate of IUAs in these women. Some background Up to a third of women who have a miscarriage need a dilation and curettage procedure for a miscarriage. A...

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Posted by Medivizor on Dec 30, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some...

Research Posts on Medivizor

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Evaluating the effectiveness and safety of adding oxaliplatin (3 months vs 6 months) to 6 months of fluoropyrimidine after surgery in patients with stage II or III colon cancer.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the long-term effectiveness and safety of bosutinib versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia.

Comparing the effectiveness and safety between biodegradable and durable polymer drug-eluting stents in patients with acute coronary syndrome.

Evaluating the effectiveness of fulvestrant plus capivasertib in patients with aromatase inhibitor-resistant estrogen receptor-positive, HER2-negative advanced breast cancer.

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Recommendations for carbohydrate-restricted diets and intermittent fasting in patients with obesity, type 2 diabetes mellitus, and hypertension.

Does hyaluronic acid gel reduce intrauterine adhesions after surgery in women with miscarriage?

Comparing the safety of palbociclib combined with fulvestrant or letrozole in HR+/HER2- advanced breast cancer

Categories

Recent Posts

Archives

Research Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email